Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.

Yahoo

a day ago

I have owned Johnson & Johnson in the past.
I like the company's business and its strong history of rewarding investors.
There's one problem I just can't get past today.
10 stocks we like better than Johnson & Johnson ›
Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices. And it is an industry leader in both spaces. There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore. And the shadow from that cloud is why I just can't justify buying Johnson & Johnson today.
When I look for stocks, I generally start with the dividend. And I don't look at the yield, instead focusing on the dividend growth streak. The longer a company has increased its dividend, the better, since only financially strong and well-run companies can hike the dividend year in and year out. J&J's streak is a huge 63 years, making it a Dividend King. I own a lot of Dividend Kings because I believe it is a clear indication that a business is well run.
I also look at dividend yield. On that front, J&J's dividend yield is roughly 3.4% today. That's well above the S&P 500 index's 1.2% average yield and the average 1.7% in the healthcare sector. But, more to the point, it happens to be toward the high end of the historical yield range for Johnson & Johnson. That suggests this reliable dividend stock is not only offering an attractive yield, but it also looks attractively priced.
On the valuation front, more traditional valuation metrics clearly back up the value proposition. J&J's price-to-sales, price-to-earnings, and price-to-book value ratios are all below their five-year averages. I haven't discussed the actual business, and Johnson & Johnson already looks like a strong buy.
The business, meanwhile, just so happens to be one of the largest in the pharmaceutical and medical device spaces. J&J has the size and scale to invest heavily in research and development, regularly bringing out attractive new products. It has manufacturing, marketing, and distribution prowess that few can match. And it is generally a very well-respected supplier, so buyers are happy to work with Johnson & Johnson. And still I won't buy it and think that most others should avoid it, too.
The problem with Johnson & Johnson is that I just can't overlook its talcum powder products. Or, more precisely, the class action lawsuits involving its talcum powder products. Past users claimed that J&J's talcum powder causes cancer. J&J denies this and is fighting the civil claims in court. The lawsuit numbers and liabilities are huge, well into the thousands of claimants and billions of dollars. To put some figures on it, there are over 60,000 lawsuits against J&J, and it recently tried to settle the issue with a $10 billion class action settlement offer. The details of the offer didn't pass muster with the judge overseeing the case, and it was denied.
My real issue, however, isn't just the potential cost. It is how uncertain the outcome is in what amounts to a super high-profile problem. If the class action case goes to a jury trial, there's no telling what happens, and the case could linger for years as both sides continue to fight, as they almost certainly will. And, worse, J&J can't discuss the problem with shareholders because it is a sensitive legal issue.
I don't blame management for not talking about the details of the lawsuits. The legal decisions J&J makes have to be kept private. But, at the same time, investors are mostly left in the dark as to what the company is going to do and why. I don't mind owning companies facing hardship, and I think J&J will survive the legal headwinds it faces. But from experience, I know I don't want to own companies that aren't able to discuss in reasonable detail what they are doing about the hardships they face. So, I can't, in good conscience, suggest anyone buy Johnson & Johnson because I wouldn't buy the stock myself right now.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,731!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $945,846!*
Now, it's worth noting Stock Advisor's total average return is 818% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It. was originally published by The Motley Fool